BioArctic AB (publ), a Swedish research based biopharma company, announced that the US Patent and Trademark Office (USPTO) published an Issue of Notification of granting the company’s patent application US 14/361,650 for a method with the medical device, which is one of the components in the product candidate SC0806. The notification states that the US patent 9,895,234 will be granted and enters into force on February 20, 2018.

The patent will provide important protection for methods of treatment of patients with complete spinal cord injury. The patent protection is in line with the company’s strategy to protect important products through patents. A corresponding patent has previously been granted in China and recently in Australia.

SC0806 is a novel product under development for the treatment for patients with complete spinal cord injury. The product candidate is currently in an ongoing phase 1/2 clinical trial. The first patient was treated in 2016 at Karolinska University Hospital, Sweden. The product candidate is a combination of a biodegradable medical device and a drug substance (FGF1) designed to support nerve regeneration across the injured area in the spinal cord. The product obtained orphan drug designation in 2010 in EU and in 2011 in the US, which gives the company 10 and 7 years of market exclusivity in Europe and the US, respectively.

BioArctic has received funding from the European Union’s Horizon 2020 Research and Innovation Program under Grant Agreement No. 643853 to perform a clinical study with SC0806.

BioArctic AB (publ) is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease.